# Comparison of analytical performance and economic value of two biosurveillance methods for tracking SARS-COV-2 variants of concern

**Authors:** Nicholas P. Pinkhover, Kerriann M. Pontbriand, Kelli P. Fletcher, Eduardo Sanchez, Kenneth Okello, Liam M. Garvey, Alex Pum, Kurvin Li, Gabriel DeOliveira, Teddie Proctor, Jelena D. M. Feenstra, Océane Sorel, Manoj Gandhi, Jared R. Auclair

PMC · DOI: 10.1128/spectrum.03484-23 · 2024-01-11

## TL;DR

This study compares two methods for tracking SARS-CoV-2 variants: whole-genome sequencing and PCR mutation panels, finding that PCR panels are faster, more cost-effective, and reliable for biosurveillance.

## Contribution

The study demonstrates that standardized PCR mutation panels offer a scalable and economically feasible alternative to whole-genome sequencing for SARS-CoV-2 variant detection.

## Key findings

- PCR mutation panels identified 77 out of 78 SARS-CoV-2 variants with high accuracy.
- PCR panels detected emerging Omicron variant earlier than WGS in some cases.
- PCR-based biosurveillance is more cost-effective and faster than whole-genome sequencing.

## Abstract

The development of biosurveillance programs with strong analytical performance and economically accessible protocols is essential for monitoring viral pathogens. Throughout the COVID-19 pandemic, whole-genome sequencing (WGS) has been the prevailing technology for SARS-CoV-2 variant of concern (VOC) detection. While WGS offers benefits, it is a lengthy process, financially and technically straining for scalable viral tracking. The aim of this study was to compare the analytical performance and economic feasibility of WGS and PCR mutation panels for distinguishing six known VOCs: Alpha (B.1.1.7 and Q.4), Gamma (P.1), Delta (B.1.617.2 and AY.4.2), and Omicron. (B.1.1.529.1). In all, 78 SARS-CoV-2-positive samples were collected from April to December 2021 at Northeastern University (Cabot Testing Site, Boston, MA, USA) for genotyping PCR and WGS analysis. MagMax Viral/Pathogen II Nucleic Acid Isolation and TaqPath COVID-19 Combo Kits were used for RNA extraction and SARS-CoV-2 confirmation. VOC discrimination was assessed using two TaqMan SARS-CoV-2 single nucleotide polymorphism (SNP) assay layouts, and Ion Torrent WGS. In November 2021, the mutation panel demonstrated marked versatility by detecting the emerging Omicron variant reported by South Africa. SNP panel analysis yielded the following 78 VOC identifications: Alpha B.1.1.7 (N = 20), Alpha Q.4 (N = 3), Gamma P.1 (N = 1), Delta B.1.617.2 (N = 30), Delta AY.4.2 (N = 3), and Omicron B.1.1.529.1 (N = 20) with one undetermined (N = 1) sample. Genotyping mutation panels designated lineages in 77 of 78 samples, 46/78 were confirmed by WGS, while 32 samples failed WGS lineage assignment. RT-PCR genotyping panels offer pronounced throughput and sensitivity and provide an economically advantageous technique for SARS-CoV-2 biosurveillance.

The results presented in our manuscript demonstrate how the value of simplistic and reliable molecular assays coupled with the core scientific principle of standardization can be overlooked by the charm of more sophisticated assays and instrumentation. This effect can often be amplified during tumultuous public health events, such as the COVID-19 pandemic. By adapting standardized PCR mutation panels to detect prominently circulating SARS-CoV-2 variants, we were able to better assess the potential health impacts of rising positivity rates and transmission clusters within the Northeastern University population. While several literature publications utilizing genotyping PCR and NGS have a similar scope to ours, many investigations lack sufficiently standardized genotyping PCR and NGS bioinformatics inclusionary/exclusionary criteria for SARS-CoV-2 variant identification. Finally, the economic benefits of standardized PCR mutation panels would allow for global implementation of biosurveillance, rather than reserving biosurveillance to more economically developed nations.

## Linked entities

- **Diseases:** SARS-CoV-2 (MONDO:0100096), COVID-19 (MONDO:0100096)

## Full-text entities

- **Diseases:** COVID-19 (MESH:D000086382)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10845967/full.md

---
Source: https://tomesphere.com/paper/PMC10845967